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Purpose: To determine levels of Peptidyl arginine deiminase 2 (PAD2) and its product protein-bound citrulline in cadaver
eyes that suffered from normal tension glaucoma (NTG) compared to primary open angle glaucoma (POAG), and controls.
Methods: Western analysis, ELISA, and immunohistochemical analysis were performed with human tissues.
Results: We report over expression of PAD2 and higher levels of its product protein-bound citrulline in the optic nerve
of normal tension glaucoma patients (NTG).
Conclusions: This is the first report demonstrating that like in POAG, NTG also possesses elevated levels of both PAD2
and protein-bound citrulline.
Glaucomas are a group of irreversible blinding diseases
that are divided into two categories, primary when ascribed to
no previous injury and illness and secondary when it can be
attributed to a previous incident [1]. Normal tension glaucoma
(NTG)  in  either  category  is  a  type  of  glaucoma  where
intraocular pressure (IOP) of the subjects remains within the
normal levels [2]. Primary open angle glaucoma (POAG) is
usually the most prevalent form. The intraocular pressure is
normally increased in glaucoma due to an imbalance between
aqueous humor production and outflow and is thought to be a
major risk factor for development of glaucoma [1,3]. Aqueous
humor  is  a  clear  fluid  that  serves  vital  functions  like
nourishing the cornea and the tissues in the anterior chamber
[4]. Glaucoma is characterized by damage to the optic nerve
termed  glaucomatous  optic  neuropathy  (GON).  The  optic
nerve damage is clinically measured as changes in visual
acuity using static perimetry. Damage to the optic nerve is
usually late onset and progressive in nature.
The  pathologic  process  of  glaucoma  remains  poorly
understood. Understanding molecular changes in glaucoma
will allow gaining an insight into the pathologic process and
may provide value in predicting glaucoma susceptibility. The
optic nerve damages are difficult to assess as those changes
locally occur in the cells in the optic nerve. There is no good
spontaneous animal model of glaucoma available that enables
extensive  invasive  analyses  in  vivo  and  in  vitro  to
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simultaneously determine clinical disease progression while
enabling molecular analysis although genomic and proteomic
analyses  on  human  cadaver  tissues  have  provided  some
insight. Whereas the changes in mRNA levels unrevealed by
genomics does not always correlate with functional proteins
they provide important insight. Proteomic analysis of primary
open angle glaucoma (POAG) cadaver tissues and subsequent
analysis  has  revealed  elevated  levels  of  peptidylarginine
deiminase  type  2  (PAD2)  and  its  product  protein-bound
citrulline [5]. However, levels of PAD2 and that of protein-
bound citrulline have not been investigated in cadaver eyes
that had normal tension glaucoma. We present our findings of
elevated  levels  of  PAD2  and  protein-bound  citrulline  in
normal tension glaucoma patients. Our results also further
corroborate previous proteomic findings in POAG patients.
METHODS
Tissue  procurement:  Donor  eyes  from  normal  (control),
POAG, and NTG cadavers were enucleated within 72 h of
death  and  obtained  from  the  National  Disease  Research
Interchange,  Philadelphia,  PA  and  the  Florida  Lions  Eye
Bank,  Largo  Medical  Center  Hospital,  Largo,  FL.  The
available medical and ophthalmic histories of cadaver eyes
were  recorded  (Table  1).  The  controls  eyes  lacked  optic
neuropathy.  Glaucomatous  and  age-matched  normal  eyes
from donors were used in this study (Table 1). Research was
conducted following the tenets of the Declaration of Helsinki.
The optic nerve was dissected from the globe. A small incision
was made with a scalpel and the entire retinal tissue attached
to the optic nerve was excised with a pair of scissors. The
dissected optic nerve tissue comprising optic nerve head and
the stock (usually 5–7 mm) was subjected to removal of fat
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1654by  trimming  the  outer  part  of  the  stock  and  subjected  to
subsequent protein extraction. The globe was subjected to
other analysis not related to research mentioned here.
Western analyses: Protein was extracted from the optic nerve
by  homogenization  in  125  mM  Tris-Cl  buffer,  pH  7.0,
containing 100 mM NaCl, 5 mM dithiothreitol, 0.1% Triton
X-100, 0.5% Tween-20, and 0.5% SDS. Insoluble material
was removed by centrifugation (8,000× g for 5 min), and
soluble protein quantified by the Bradford assay. Western
analyses  were  performed  with  5  µg  of  protein,  4%–20%
gradient gels (Invitrogen Inc., Carlsbad, CA), electroblotted
to  PVDF  membrane  and  probed  with  antibodies:  rabbit
polyclonal antibody against PAD2 (Abcam Inc., Cambridge,
MA),  mouse  antibody  to  glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; Millipore Corporation, Billerica,
MA) and against protein-bound monoxime modified citrulline
(Millipore Corporation). For quantitative western analyses,
secondary antibodies conjugated with horseradish peroxidase
were used.
Enzyme  linked  immunosorbent  assay  (ELISA)  analyses:
About 5 μg of purified in vitro deiminated BSA (BSA) or
5 μg of protein extract was centrifuged at 8,000× g for 5 min
and  100  μl  clear  solution  was  transferred  to  wells  in  a
multiwell plate (Costar plates-e Bioscience Inc., San Diego,
CA)  and  incubated  for  20  min  at  room  temperature.
Recombinant  cellular  retinaldehyde  binding  protein
(CRALBP) produced in E. coli was used as non-deiminated
control.  The  recombinant  CRALBP  and  in  vitro  fully
deiminated BSA (5 μg) was used as non-deiminated and fully
deiminated  control,  respectively.  Proteins  were  incubated
with 40 μl/well of 1:1 reagent A and B from a citrulline kit
(17–347; Millipore Corporation) at 37 °C for 90 min. The
supernatant was discarded and the plate was washed with
PBS. The plates were blocked with 1% BSA for 1 h, washed
with  PBS,  and  incubated  for  1  h  with  rabbit  polyclonal
antibody against modified citrulline. After washes with PBS,
plates were incubated with the secondary antibody coupled
with alkaline phosphatase for 1 h, washed with PBS and
incubated  with  phosphatase  substrate  (100  μl/well)  in
diethanolamine  buffer  pH7.5.  The  absorbance  was  then
measured at 405 nm on a plate reader. For detection of PAD2,
the reagent A and B incubation step was omitted and a rabbit
polyclonal antibody against PAD2 (ab16478; Abcam Inc.)
was used for detection using an identical procedure. Purified
CRALBP alone and recombinant purified PAD2 (5 μg) on
purified  CRALBP  under  identical  conditions  served  as
negative and positive control respectively. ELISA analyses
results are expressed as mean±standard deviation. Statistical
analysis was performed for each sample at every experimental
point shown, compared to 0.0 using the two tailed one-sample
t-test and was found significantly different from 0.0 at each
time point by the one-sample t-test: p<0.05.
PAD2 activity assay: Activity of PAD2 was measured using
a monooxime treatment followed by assessment of optical
density using suitable modification or previous procedures
[6]. Briefly, the reaction mixtures containing 100 mM Tris-
TABLE 1. DETAILS OF TISSUE DONORS.
Age Gender Race Diseases C/D ratio Mean defect IOP
Control donors
62 M Caucasian Cardiac arrest N/A N/A 11
70 F Caucasian Cardiac arrest N/A N/A N/A
66 M Caucasian Cardiac arrest N/A N/A N/A
77 F Caucasian Cardiac arrest N/A N/A 14
75 M Caucasian Cardiac arrest N/A N/A N/A
74 F Caucasian Cardiac arrest N/A N/A N/A
Glaucoma donors
65 F Caucasian Cardiac arrest 1 −11 14.5
74 M Caucasian Cardiac arrest 0.7 −12 16
72 F Caucasian Cardiac arrest 0.8 −10 14
80 M Caucasian Cardiac arrest 0.6 −11 16.5
74 F Caucasian Cardiac arrest 0.8 −10 16
78 F Caucasian Cardiac arrest 0.7 −9 14
72 F Caucasian Cardiac arrest 0.8 −7 22
75 M Caucasian Cardiac arrest 0.7 −8 24
In the table, C/D ratio=Cup to disk ratio; GHT=Glaucomatous hemifield test for all glaucoma donors were outside normal limit;
All donor eyes used in this study that had records of automated static perimetry used a full threshold 24–2 test procedure. All
controls had a visual acuity of 20/30 or better, no cataract, glaucoma or any other known eye disease. Mean defect have been
rounded off to single digit numbers. The IOP measurement refers to last known measurement before death.
Molecular Vision 2010; 16:1654-1658 <http://www.molvis.org/molvis/v16/a178> © 2010 Molecular Vision
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ethyl ester (BAEE), and an appropriate amount of protein
extract (5 μg/sample) in a final volume of 50 μl were incubated
at 37 °C for 3 h. The reaction of enzyme activity was stopped
by adding 10 μl of 5 M perchloric acid and the perchloric acid-
soluble fraction was subjected to 150 μl of carbidino detection
reagent,  which  was  assembled  freshly  from  its  two
components  with  one  of  part  A  containing  0.5%  diacetyl
monoximine and 0.01% thiosemicarbazide added to two of
parts B containing 0.25 mg of FeCl3/ml in 24.5% sulfuric acid
Figure  1.  Elevated  PAD2  and  protein-bound  citrulline
immunoreactivity in glaucomatous optic nerve. A: Representative
western analyses with monoclonal anti-PAD2 of protein extracts
from human optic nerve tissue (~25 µg per lane) demonstrating the
presence of elevated levels of PAD2 was detected in glaucomatous
tissues.  Lower  panel  shows  the  GAPDH  immunoreactivity
indicating equal protein loading. B: Western analyses with rabbit
polyclonal antibody to citrulline (25 µg protein per lane). Prior to
applying antibody, membrane with transferred proteins was treated
with 2,3-butanedione monooxime and antipyrine in a strong acid
environment to modify the protein-bound citrullines to enable the
detection with the antibody. Proteins were extracted from the optic
nerve of Caucasian cadaver donor eyes: age and gender are indicated.
(H2SO4) and 17% phosphoric acid (H3PO4). The reaction was
mixed vigorously and heated at 65 °C for 5 min. After heating,
samples were cooled to room temperature and the absorbance
was measured at 435 nm in a spectrophotometer. As a control,
purified recombinant cellular retinaldehyde binding protein
(CRALBP) prepared in bacteria was subjected to recombinant
PAD2 treatment and re-purified.
Immunohistochemistry: Histological evaluations were made
following previously published protocols for protein-bound
citrulline.  The  4%  paraformaldehyde  in  phosphate  buffer
fixed  and  subsequently  paraffin  embedded  anterior  eye
sections  (about  10  µm)  were  prepared  and  stained  with
antibodies to PAD2 and protein-bound citrulline. Presence of
protein-bound  citrulline  was  verified  using  fluorescence
analyses using Alexa 488 and Alexa 594 coupled secondary
antibodies (Invitrogen Molecular Probes, Eugene, OR). To
ensure identical processing and uniform exposure, controls
(without antibody and primary antibody treated sections) were
examined side by side on the same slide. Fluorescence images
were  obtained  using  a  Leica  TCS-SP5,  laser  scanning
confocal microscope (Leica, Exton, PA). A series of 1 µm xy
(en face) images were collected and summed for an image
representing  a  three-dimensional  projection  of  the  entire
10 µm section. Confocal microscopic panels were composed
using Adobe Photoshop 8.0.
Figure 2. The PAD2 and level of deimination using ELISA analyses
as described in methods. A and B: PAD2 level represented by hollow
bars and dotted bars for control and glaucomatous donors. C and
D: Level of deimination are represented by hollow bars and dotted
bars for control and glaucomatous donors respectively. The results
are standard deviation of three independent experiments.
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Elevated PAD2 was detected in normal tension glaucoma
donors as well as in POAG donors (Figure 1A and Figure
2A,B). Commensurate with elevated PAD2, elevated protein-
bound  citrulline  (Figure  1B  and  Figure  2C,D)  was  also
detected in NTG optic nerve compared to control. Activity
measurement  showed  elevated  PAD2  in  protein  extract
derived from NTG and POAG donors compared to control
(Figure 3). Elevated PAD2 activity is commensurate with
elevated PAD2 immunoreactivity as well as that for protein-
bound  citrulline  (Figure  1).  We  also  investigated  protein-
bound citrulline immunoreactivity (product of PAD2 activity)
using immunohistochemistry in optic nerve sections of NTG
eyes (Figure 4A,B). The immunohistochemical comparison
of protein-bound citrulline immunoreactivity, commensurate
with western (Figure 1B) and ELISA (Figure 2) analyses
showed elevated immunoreactivity in the NTG compared to
control eyes. All sections subjected to immunohistochemical
analyses  were  also  subjected  to  relative  intensity
measurement with after normalization of measurement area
which  showed  relatively  elevated  levels  of  protein-bound
citrulline in NTG eyes compared to controls (Figure 4C).
DISCUSSION
We  report  here  for  the  first  time,  elevated  PAD2
immunoreactivity  (Figure  1A),  activity  (Figure  3)  and
immunoreactivity for protein-bound citrulline (Figure 4) in
Figure 3. Elevated PAD2 activity in glaucomatous optic nerve. PAD
activity was measured as described in the methods and absorbance
at 435 nm has been shown.
normal tension glaucoma eyes compared to controls. While
elevated PAD2 and protein-bound citrulline has been shown
in POAG [5], the same has not been previously investigated
in  NTG.  PAD2  catalyzes  conversion  of  protein-bound
arginine  into  citrulline  (but  from  free  arginines)  termed
deimination [7]. There exists no known enzyme to reverse the
posttranslational deimination rendering this modification a
long-term modification that is reversed only with degradation
of proteins [8]. Previously, PAD2 and elevated deimination
has been implicated in neurodegenerative changes [9,10] and
in  kainic-acid  evoked  neurodegeneration  [11].  Although
unbiased  proteomic  analyses  showed  PAD2  and  elevated
levels of PAD2 and deimination, its role in glaucomatous
neurodegeneration remains unclear. It appears that in response
to environmental stimuli, different cells of neuronal systems
express  different  levels  of  PAD2,  whereas  the  PAD2
expression  undergo  a  decrease  in  response  to  certain
environmental stimuli in neurons that of other cell types, for
example, in astrocytes it increases [8]. Further investigation
will reveal the detailed mechanistic insight of the role of
relatively  long-term  posttranslational  modification  of
deimination  in  the  glaucomatous  neurodegeneration.  Our
discovery of elevated deimination in NTG suggests possible
underlying common mechanistic features in all glaucomatous
optic neuropathies.
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Figure 4. Representative immunohistochemical analyses of NTG (70
F) and control (72F) donor optic nerve sections. A: Immunoreactivity
for protein-bound citrulline detected by a rabbit polyclonal antibody
to citrulline after monoxime modification as described in methods.
B: Merged image of anti-citrulline with DAPI. C: Control donor
section probed for immunoreacitivty with anti-citrulline. D: Merged
image  of  anti-citrulline  and  DAPI  for  control  donor  section.  E:
Densitometric  analysis  of  immunohistochemical  detection  of
protein-bound citrulline in NTG eyes. The data was analyzed using
Image J software.
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